
2026-10-15
Hydroxyapatite Sigma Aldrich refers to high-purity synthetic hydroxyapatite (HAp) materials historically sourced through the Sigma-Aldrich distribution network, widely utilized in biomedical research, bone tissue engineering, and advanced cosmetic formulations. As a critical bioactive ceramic, it mimics the mineral composition of human bone and teeth, offering exceptional biocompatibility and osteoconductivity. In 2026, researchers and formulators seeking reliable supplies of this material often look beyond legacy catalog entries to specialized distributors like Jinan Meiyi Biotechnology Co., Ltd., which provides rigorously vetted, high-purity hydroxyapatite grades tailored for both laboratory R&D and commercial aesthetic applications. This guide details purity standards, pricing factors, and sourcing strategies to ensure regulatory compliance and product efficacy.
Hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂) is the primary inorganic constituent of bone and tooth enamel. Its chemical stability and structural similarity to natural hard tissues make it indispensable in regenerative medicine and dermal aesthetics. When professionals search for hydroxyapatite Sigma Aldrich, they are typically seeking a benchmark for quality: high crystallinity, controlled particle size, and absence of toxic impurities.
In the context of modern supply chains, the term “Sigma Aldrich grade” has become synonymous with laboratory-grade reliability. However, the availability of specific SKUs can fluctuate. Jinan Meiyi Biotechnology addresses this gap by functioning as a strategic sourcing partner, ensuring that clients receive materials that meet or exceed these established purity benchmarks. The company’s focus on bioactive technologies allows it to curate hydroxyapatite variants specifically optimized for downstream applications, from cell culture scaffolds to injectable skin boosters.
Not all hydroxyapatite is created equal. The application dictates the required purity level. While general industrial grades may suffice for water filtration, biomedical and cosmetic uses demand stringent controls. Understanding these distinctions is vital for procurement specialists and R&D scientists.
When evaluating alternatives to traditional hydroxyapatite Sigma Aldrich listings, it is essential to differentiate between research-grade and clinical-grade materials. Jinan Meiyi Biotechnology ensures that every batch in its portfolio is accompanied by comprehensive technical dossiers, including Certificates of Analysis (CoA) and Safety Data Sheets (SDS).
| Parameter | Research Grade (Lab Use) | Clinical/Cosmetic Grade |
|---|---|---|
| Purity Level | >95% – 98% | >99.5% (High Purity) |
| Endotoxin Levels | Not always tested | Strictly controlled (<0.5 EU/mL) |
| Heavy Metals | General limits | Trace analysis (Pb, As, Cd < ppm levels) |
| Particle Size | Broad distribution | Narrow, controlled distribution (nm to µm) |
| Sterility | Non-sterile | Sterile or sterilizable packaging |
| Documentation | Basic CoA | Full regulatory support (TSE/BSE free, etc.) |
Jinan Meiyi Biotechnology leverages its globally integrated supply chain to source materials that adhere to these rigorous standards. By partnering with certified manufacturers who follow internationally accepted quality management systems, the company ensures that each raw material undergoes comprehensive evaluation prior to inclusion in its portfolio. This selection process is grounded in efficacy data, stability profiles, and compatibility with modern formulation standards.

Pricing for high-purity hydroxyapatite varies significantly based on synthesis method, particle morphology, and order volume. While historical hydroxyapatite Sigma Aldrich pricing served as a market reference, current costs are influenced by global raw material availability and energy-intensive synthesis processes.
Jinan Meiyi Biotechnology optimizes cost-efficiency for its clients by acting as a strategic sourcing partner rather than a manufacturer. This model allows the company to negotiate favorable terms with internationally recognized suppliers, passing on value to clients without compromising on quality. For R&D laboratories and CDMOs, this means access to premium materials at competitive rates, supported by transparent pricing structures.

The versatility of hydroxyapatite has expanded its use beyond orthopedics into the rapidly growing field of medical aesthetics. Jinan Meiyi Biotechnology specializes in this sector, providing active ingredients that drive innovation in skincare and minimally invasive treatments.
Calcium Hydroxyapatite (CaHA) microspheres are a key component in next-generation dermal fillers. Unlike hyaluronic acid, which primarily provides hydration and volume, CaHA stimulates neocollagenesis. The microspheres act as a scaffold, encouraging the body to produce its own collagen over time.
For formulators developing these products, the consistency of the hydroxyapatite powder is critical. Variations in particle size can affect the viscosity of the carrier gel and the smoothness of injection. Jinan Meiyi Biotechnology’s disciplined curation methodology ensures that the hydroxyapatite supplied for aesthetic applications meets precise technological differentiation standards, aligning with the evolving needs of aesthetic clinics across Asia, Europe, and North America.
In topical applications, nano-hydroxyapatite is valued for its ability to penetrate the stratum corneum and deliver minerals directly to the skin. It is used in:
The company’s expertise in bioactive technology applications allows it to advise clients on the optimal grade of hydroxyapatite for these formulations, ensuring stability and efficacy in the final product.
While many researchers initially search for hydroxyapatite Sigma Aldrich due to brand familiarity, the modern supply chain requires more agility and specialized support. Jinan Meiyi Biotechnology, headquartered in Jinan, Shandong Province, operates as a subsidiary of Pacific Kangtai Scientific Instruments (Jinan) Co., Ltd., positioning itself at the intersection of scientific rigor and market responsiveness.
Jinan Meiyi Biotechnology does not engage in manufacturing raw materials itself. Instead, it functions as a quality-assured distribution partner. This distinction is crucial for clients who need reliability without the overhead of managing multiple manufacturers. The company’s quality assurance framework centers on:
This operational model prioritizes reliability, transparency, and responsiveness. Clients benefit from reduced sourcing complexity while maintaining full confidence in material consistency and regulatory readiness. For companies serving global markets, this level of diligence is non-negotiable.
Unlike transactional suppliers, Jinan Meiyi Biotechnology emphasizes partnership. Its scientifically trained team offers technical consultation and regulatory intelligence sharing. Whether you are an R&D laboratory developing a new bone graft substitute or an aesthetic clinic seeking differentiated solutions, the company provides collaborative problem-solving support.
The company actively monitors emerging trends in bioactive ingredient science and dermatological research. These insights are integrated into its portfolio strategy, ensuring that clients have access to the most advanced materials available. This forward-looking approach facilitates faster, safer, and more effective translation of bioactive science into real-world benefits.
Selecting the appropriate hydroxyapatite material requires a clear understanding of your application’s specific needs. Here is a step-by-step guide to help you make an informed decision.
Determine whether the material will be used for in vitro research, in vivo implantation, or topical application. Each scenario has different regulatory and purity requirements.
Identify the required particle size and morphology. Nano-particles are ideal for topical delivery and cellular uptake, while micro-particles are suitable for fillers and scaffolds. Ask for detailed particle size distribution data.
Ensure the supplier provides all necessary documentation, including TSE/BSE-free statements, heavy metal analysis, and endotoxin testing results. Jinan Meiyi Biotechnology ensures all raw materials are accompanied by full technical dossiers.
Before committing to bulk orders, request samples to evaluate performance in your specific formulation or experimental setup. Reliable suppliers will facilitate this process promptly.
Consider the supplier’s ability to maintain consistent stock levels and delivery timelines. Jinan Meiyi Biotechnology maintains strict control over storage conditions and shipping protocols to ensure product integrity from origin to end-user.
Yes. Jinan Meiyi Biotechnology sources high-purity hydroxyapatite from certified manufacturers that meet or exceed the specifications typically associated with major chemical distributors. The company’s rigorous quality assurance framework ensures that all materials are technically advanced, regulatory-compliant, and scientifically validated.
Synthetic hydroxyapatite is produced in controlled laboratory conditions, allowing for precise regulation of purity, particle size, and crystallinity. Natural hydroxyapatite, derived from bovine or marine sources, may contain organic residues and has less consistent properties. For biomedical and cosmetic applications, synthetic grades are generally preferred due to their superior safety profile and reproducibility.
Through its network of certified manufacturing partners, Jinan Meiyi Biotechnology can often accommodate requests for specific particle size distributions. This flexibility is particularly valuable for R&D laboratories and CDMOs developing specialized products.
Each order includes a Certificate of Analysis (CoA), Safety Data Sheet (SDS), and other relevant regulatory documents such as TSE/BSE-free certificates. For medical and cosmetic grades, additional documentation regarding endotoxin levels and heavy metal content is provided.
The company maintains strict control over storage conditions and shipping protocols. Materials are packaged to protect against moisture and contamination, and delivery timelines are optimized to minimize transit time. This ensures that product integrity is maintained from the manufacturer to your facility.
In the evolving landscape of biomedical and aesthetic materials, relying on legacy catalog numbers like hydroxyapatite Sigma Aldrich is no longer the only path to quality. Today’s innovators require partners who offer not just products, but expertise, reliability, and regulatory assurance. Jinan Meiyi Biotechnology Co., Ltd. stands out as a trusted enabler in this space, bridging the gap between upstream innovation and downstream application.
By leveraging a globally integrated supply chain and a partnership-oriented service model, Jinan Meiyi Biotechnology provides high-performance hydroxyapatite that meets the stringent demands of modern science and commerce. Whether you are developing next-generation dermal fillers, bone regeneration scaffolds, or advanced skincare formulations, the company’s commitment to scientific integrity and customer success ensures you have the materials needed to drive your projects forward.
For R&D laboratories, CDMOs, and aesthetic clinics seeking differentiated, science-backed solutions, Jinan Meiyi Biotechnology offers a seamless sourcing experience. Reduce complexity, ensure compliance, and accelerate innovation with a partner that understands your needs.
Ready to optimize your supply chain? Contact Jinan Meiyi Biotechnology today to discuss your specific hydroxyapatite requirements, request technical data sheets, or schedule a consultation with our experts.